Characterization of Protein Therapeutics using Mass Spectrometry

GUODONG CHEN, PHD, has extensive pharmaceutical research experience in major pharmaceutical companies, including Eli Lilly and Company, Schering-Plough and Bristol-Myers Squibb. Currently, he heads the analytical/mass spectrometry group at Bristol-Myers Squibb’s Princeton site in support of drug discovery programs and development projects in small molecule pharmaceuticals and biologics. He has over 65 research publications in peer-reviewed journals and book chapters, and three edited/co-edited books in pharmaceutical analysis. His other contributions to the scientific community include over 80 presentations at scientific conferences and academic institutes; service as a short course instructor, as session chair at various scientific forums, and as a reviewer for journals. He received his Ph.D. in Analytical Chemistry from Purdue University under the direction of Professor R. Graham Cooks. 

Characterization of Protein Therapeutics by Mass Spectrometry: Recent Developments and Future Directions.- The Use of Mass Spectrometry to Characterize the Metabolism of Peptide Therapeutics.- Quantitative Analysis of Biologics Using Mass Spectrometry.- Maximizing Structural Information from Whole Protein Tandem Mass Spectrometry.- Disulfide Linkages of an Albumin Fusion Protein.- Detailed Structural Characterization of Monoclonal Antibodies.- Application of Protein Mass Spectrometry in Impurity and Degradant Characterization.- Mass Spectrometry Methods to Analyze Higher Order Structure of Protein Therapeutics by Chemical Footprinting.- Aglycosylations Alters Protein Conformation in Antibodies Engineered with Specific Effector Functions Using HDX-MS.- Characterizing Biotherapeutic Protein 3D Structures by Electrospray Ion-Mobility Mass Spectrometry.- Oxford University, Characterization of Assemblies of Proteins by Mass Spectrometry.